TG THERAPEUTICS, INC.
In the published model solve dated 2026-Q2, anchored at $49.87, TG THERAPEUTICS, INC. (TGTX) is priced for today's economics sustained for ~20.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• TG Therapeutics is a one-drug company that reached profitability: BRIUMVI, its intravenous anti-CD20 antibody for relapsing multiple sclerosis, drove first quarter 2026 total revenue of $204.9 million, up from $120.9 million a year earlier, with $19.8 million of net income [Source: Q1 2026 results, May 2026]. • The biggest risk is concentration meeting competition: the 10-K states BRIUMVI ⟦"directly competes with ocrelizumab, the only other approved intravenously administered anti-CD20 monoclo
Is TGTX overvalued? See what's priced in →
348 institutional managers reported holding TGTX in 13F filings for the quarter ended 2026-03-31. Together they hold about 66% of the company; the top 10 hold 41%. 58 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 30.2M shares were sold short as of the 2026-06-15 count, about 19% of shares outstanding (12.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TGTX's share count grew 9.4% over the past five years even with $199.99M spent on repurchases. It pays no dividend. Cash returned over the past three years: $199.99M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TGTX over the trailing three years: 2023: 1 buy totaling $1.01M. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TGTX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-03-02 | +4.7% | -23.9% |
| 2023-11-07 | +34.7% | +94.0% |
| 2024-03-01 | +23.8% | -9.9% |
| 2024-05-07 | +20.2% | +15.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TGTX's latest 8-K filings: 2026-08-03 (items 2.02, 9.01); 2026-06-12 (items 5.07); 2026-06-03 (items 8.01, 9.01); 2026-05-27 (items 8.01, 9.01); 2026-05-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.